Merck & Co to Acquire Acceleron Pharma in Rare Disease Drug Push
Merck & Co. has agreed for purchasing the company ‘Acceleron Pharma Inc., for around 11.5 billion dollars, along with building out the portfolio of the therapies for the purpose of treating the rare diseases. The shareholders of the company ‘Acceleron’ are going to be getting a share of 180 dollars in cash, along with a […]
Continue Reading